Gastric cancer (commonly known as stomach cancer) typically begins in the upper sac of the abdomen. It is fairly uncommon in the United States but it's more common in China and Japan. Because it is typically diagnosed in its later stages, its prognosis is common poor. In early gastric cancer (EGC), the cancer has not spread more deeply than the submucosa. Specifically, it is defined as an adenocarcinoma that is limited to the mucosa or submucosa, irrespective of lymph node metastasis. EGC has a significantly better prognosis than do more progressed stages of gastric cancer. Risk factors for stomach cancer include: poor diets, anemia, smoking, family history, stomach inflammation, and some stomach infections. Treatments of stomach cancer include surgery, radiation therapy, chemotherapy, and targeted drugs. There are four stages of stomach cancer that affect the treatment plan based on severity of the cancer. Many of the stages are divided into subgroups as well that give more detail to the progression of the cancer.
Early Gastric Cancer Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Early Gastric Cancer below!
For more information on how to use Laverne, please read the How to Guide.
We have 1948 products for the study of Early Gastric Cancer that can be applied to Western Blot, Chromatin Immunoprecipitation, Immunocytochemistry/Immunofluorescence, Flow Cytometry, Immunohistochemistry, Chromatin Immunoprecipitation (ChIP) from our catalog of antibodies and ELISA kits.